BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrol idin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which qualifies this molecule as a good in vitro and in vivo tool compound. BI 1002494 exhibits higher potency in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation (IC50 = 115 nM) compared with B-cell receptor-mediated activation of B cells (IC50 = 810 nM). This may be explained by lower kinase potency when the physiologic ligand B-cell linker was used, suggesting that SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand. A 3-fold decrease in potency was observed in rat basophils (IC50 = 323 nM) compared with human basophils, but a similar species potency shift was not observed in B cells. The lower potency in rat basophils was confirmed in both ex vivo inhibition of bronchoconstriction in precision-cut rat lung slices and in reversal of anaphylaxis-driven airway resistance in rats. The different cellular potencies translated into different in vivo efficacy; full efficacy in a rat ovalbumin model (that contains an element of mast cell dependence) was achieved with a trough plasma concentration of 340 nM, whereas full efficacy in a rat collagen-induced arthritis model (that contains an element of B-cell dependence) was achieved with a trough plasma concentration of 1400 nM. Taken together, these data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated.
- Lamb, D. J.; Wollin, S. L.; Schnapp, A.; Bischoff, D.; Erb, K. J.; Bouyssou, T.; Guilliard, B.; Strasser, C.; Wex, E.; Blum, S.; Thaler, E.; Nickel, H.; Radmacher, O.; Haas, H.; Swantek, J. L.; Souza, D.; Canfield, M.; White, D.; Panzenbeck, M.; Kashem, M. A.; Sanville-Ross, M.; Kono, T.; Sewald, K.; Braun, A.; Obernolte, H.; Danov, O.; Schaenzle, G.; Rast, G.; Maier, G. M.; Hoffmann, M.
Keywords
- Administration, Oral
- Animals
- B-Lymphocytes/*drug effects/*enzymology
- Basophils/*drug effects/*enzymology
- Humans
- Male
- Mast Cells/drug effects/enzymology
- Naphthyridines/administration & dosage/*pharmacology
- Protein Kinase Inhibitors/administration & dosage/*pharmacology
- Pyrrolidines/administration & dosage/*pharmacology
- Pyrrolidinones/administration & dosage/*pharmacology
- Rats
- Syk Kinase/*antagonists & inhibitors